TDO2 demonstrates constitutive overexpression in high-grade gliomas, particularly glioblastoma(GBM), serving as an independent biomarker for tumor aggressiveness and poor prognosis (Riess et al., 2020; Wang et al., 2025). This evidence concerns the gene TDO2 and glioblastoma.